Trial intelligence / Profile preview

I2BIO-HD: Innovative Imaging and Cognitive Biomarkers to Predict Huntington’s Disease Progression

2024-516022-63-00Phase 3Authorised

Sponsor: Assistance publique - Hôpitaux de Paris
Start: Nov 2024
Modality: Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
Countries: 1

Overview

Phase 3, open-label trial of MNI-659 in Huntington disease (HD) (3 arms), sponsored by Assistance publique - Hôpitaux de Paris. Primary endpoint: Primary effect size of biomarkers over 2 years. Planned start Nov 2024; status: authorised.

Drugs

MNI-659

Conditions

Huntington disease (HD)

Beyond the preview

Go deeper on 2024-516022-63-00.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on 2024-516022-63-00.